Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Maarten Cozijnsen; Janneke Samsom; Lissy de Ridder

doi:10.1007/s40272-017-0266-9

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Maarten Cozijnsen, Janneke Samsom, Lissy de Ridder

Pediatrics

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

7 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	19-28
Number of pages	10
Journal	Paediatric Drugs
Volume	20
Issue number	1
DOIs	https://doi.org/10.1007/s40272-017-0266-9
Publication status	Published - 2018

Research programs

EMC MM-04-54-07

Access to Document

10.1007/s40272-017-0266-9

REPUB_102668-OA.pdfFinal published version, 767 KB

http://hdl.handle.net/1765/110717

Cite this

@article{998af84d11a644acabfbf2e6621cc261,

title = "Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability",

author = "Maarten Cozijnsen and Janneke Samsom and {de Ridder}, Lissy",

year = "2018",

doi = "10.1007/s40272-017-0266-9",

language = "Undefined/Unknown",

volume = "20",

pages = "19--28",

journal = "Paediatric Drugs",

issn = "1174-5878",

publisher = "Adis",

number = "1",

}

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. / Cozijnsen, Maarten; Samsom, Janneke ; de Ridder, Lissy.
In: Paediatric Drugs, Vol. 20, No. 1, 2018, p. 19-28.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

AU - Cozijnsen, Maarten

AU - Samsom, Janneke

AU - de Ridder, Lissy

PY - 2018

Y1 - 2018

U2 - 10.1007/s40272-017-0266-9

DO - 10.1007/s40272-017-0266-9

M3 - Article

C2 - 29079905

SN - 1174-5878

VL - 20

SP - 19

EP - 28

JO - Paediatric Drugs

JF - Paediatric Drugs

IS - 1

ER -